The DOI matches its Crossref record.
Decreased Anion Exchanger 2 Immunoreactivity in the Liver of Patients With Primary Biliary Cirrhosis
Open accessAbstract
Chloride–bicarbonate anion exchanger 2 (AE2) is expressed in a variety of tissues, including the liver and salivary glands, where it may participate in the generation of hydroionic fluxes into secretions. We have previously reported decreased hepatic levels of AE2 messenger RNA in patients with primary biliary cirrhosis (PBC), a cholestatic condition frequently associated with pluriglandular exocrine failure. Here we investigated the expression of AE2 protein in the liver of PBC patients. Using a monoclonal antibody against an AE2 peptide, immunohistochemistry was performed on liver biopsy specimens from subjects with normal liver (n = 7), patients with PBC (n = 13), and patients with cirrhosis or cholestasis other than PBC (n = 17 and 11, respectively). Immunostaining was graded from 0 to 7, according to its intensity and distribution. AE2 immunoreactivity was observed in normal livers, as previously reported, and in many pathological liver biopsy specimens, being mainly restricted to canaliculi and the luminal membrane of terminal and interlobular bile ducts. Canalicular and ductular scores were significantly reduced in the PBC group compared with each control group (normal liver and cirrhosis or cholestasis other than PBC), whereas no differences in immunoreactivity scores were observed among control groups. When four patients with primary sclerosing cholangitis (PSC) were analyzed, they also differed from those with PBC. These results suggest that PBC is characterized by diminished expression of AE2 in the liver. Reduced levels of this transporter protein might be involved in the pathogenesis of cholestasis in PBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Paumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
Molecular Pathogenesis of Cholestasis
Trauner, M., Meier, P. J., & Boyer, J. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391707 · Cited by 706
Molecular Pathogenesis of Cholestasis
Trauner, M., & Jansen, P. L. M. (2004) · Springer eBooks · doi:10.1007/978-1-4419-9034-1 · Cited by 610
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Banales, J. M., Huebert, R. C., Karlsen, T., Strazzabosco, M., LaRusso, N. F., & Gores, G. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0125-y · Cited by 517
Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417
“UDCA stimulates the expression of transporter proteins that are needed for biliary secretion in the liver of humans and experimental animals”
BackgroundUrsodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’
Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00092-7 · Cited by 411
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
Halilbasic, E., Claudel, T., & Trauner, M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.002 · Cited by 393
Zollner, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22646 · Cited by 362
Beuers, U., Hohenester, S., de Buy Wenniger, L. J. M., Kremer, A. E., Jansen, P. L. M., & Elferink, R. P. J. O. (2010) · Hepatology · doi:10.1002/hep.23810 · Cited by 351
Hohenester, S., de Buy Wenniger, L. M., Paulusma, C. C., van Vliet, S. J., Jefferson, D. M., Oude Elferink, R. P., & Beuers, U. (2012) · Hepatology · doi:10.1002/hep.24691 · Cited by 315
Fickert, P., Zollner, G., Fuchsbichler, A., Stumptner, C., Weiglein, A. H., Lammert, F., Marschall, H., Tsybrovskyy, O., Zatloukal, K., Denk, H., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35948 · Cited by 313
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis
Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Marschall, H.-U., Zatloukal, K., Denk, H., & Trauner, M. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00096-5 · Cited by 275
Primary biliary cirrhosis: A 2010 update
Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.027 · Cited by 274
Mechanisms of bile acid mediated inflammation in the liver
Li, M., Cai, S.-Y., & Boyer, J. L. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.06.001 · Cited by 271
New molecular insights into the mechanisms of cholestasis
Wagner, M., Zollner, G., & Trauner, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.012 · Cited by 260
Fickert, P., Zollner, G., Fuchsbichler, A., Stumptner, C., Pojer, C., Zenz, R., Lammert, F., Stieger, B., Meier, P. J., Zatloukal, K., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.25542 · Cited by 257
Banales, J. M., Sáez, E., Úriz, M., Sarvide, S., Urribarri, A. D., Splinter, P., Tietz Bogert, P. S., Bujanda, L., Prieto, J., Medina, J. F., et al. (2012) · Hepatology · doi:10.1002/hep.25691 · Cited by 250
Self-citationThe challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Melero, S., Spirlì, C., Zsembery, Á., Medina, J. F., Joplin, R. E., Duner, E., Zuin, M., Neuberger, J. M., Prieto, J., & Strazzabosco, M. (2002) · Hepatology · doi:10.1053/jhep.2002.33634 · Cited by 107
Self-citationSoluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes
Chang, J., Go, S., de Waart, D. R., Munoz‐Garrido, P., Beuers, U., Paulusma, C. C., & Oude Elferink, R. (2016) · Hepatology · doi:10.1002/hep.28550 · Cited by 70
“The present study sheds new light on the mechanism of BSIA in cholangiocytes and provides novel mechanistic insight into a potential role of AE2 downregulation in cholangiocytes of PBC patients.((5,6)) We demonstrate that BSIA in both H69 human cholangiocytes and primary mouse cholangiocytes is regulated by sAC, that…”
BackgroundHisamoto, S., Shimoda, S., Harada, K., Iwasaka, S., Onohara, S., Chong, Y., Nakamura, M., Bekki, Y., Yoshizumi, T., Ikegami, T., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.08.006 · Cited by 57
Jin, C., Jiang, P., Zhang, Z., Han, Y., Wen, X., Zheng, L., Kuang, W., Lian, J., Yu, G., Qian, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53104-9 · Cited by 56
Ursodeoxycholic acid in pregnancy?
de Vries, E., & Beuers, U. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.020 · Cited by 40
Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection
Herta, T., Kersten, R., Chang, J.-C., Hubers, L., Go, S., Tolenaars, D., Paulusma, C. C., Nathanson, M. H., Elferink, R. O., van de Graaf, S. F. J., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.009 · Cited by 25
The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects
Ronca, V., Davies, S. P., Oo, Y. H., & Lleo, A. (2025) · Hepatology · doi:10.1097/hep.0000000000001225 · Cited by 22
Metadata
- Authors
- Medina, J. F., Martínez-Ansó, E., Vázquez, J. J., & Prieto, J.
- Venue
- Hepatology
- Published
- 1997-01
- Volume
- 25
- Issue
- 1
- Pages
- 12-17
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1968447938
- Cited by
- 207
- References
- 0
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.